HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis

Fibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms. Accumulating evidence indicates that epigenetic alterations, including histone acetylation, play a pivotal role in this process. Histone acetylation...

Full description

Bibliographic Details
Main Authors:	Xing Lyu, Min Hu, Jieting Peng, Xiangyu Zhang, Yan Y Sanders
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-07-01
Series:	Therapeutic Advances in Chronic Disease
Online Access:	https://doi.org/10.1177/2040622319862697

Similar Items

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
by: Evgenii Skurikhin, et al.
Published: (2020-11-01)

Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
by: Ji-Min Li, et al.
Published: (2023-05-01)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
by: Yuji Iwanami, et al.
Published: (2022-09-01)

Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Hanjing Sheng, et al.
Published: (2022-06-01)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2021-07-01)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01)

Antifibrotic Drugs against Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis Induced by COVID-19: Therapeutic Approaches and Potential Diagnostic Biomarkers
by: Aurelio Perez-Favila, et al.
Published: (2024-01-01)

Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice
by: Yang Miao, et al.
Published: (2023-03-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
by: Jieun Kang, et al.
Published: (2021-09-01)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
by: Riitta Kaarteenaho, et al.
Published: (2022-09-01)

Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway
by: Jieting Peng, et al.
Published: (2023-02-01)

Anti-Inflammatory and Antifibrotic Potential of Longidaze in Bleomycin-Induced Pulmonary Fibrosis
by: Angelina Pakhomova, et al.
Published: (2023-09-01)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
by: Bridget F. Collins, et al.
Published: (2019-10-01)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
by: Bryan T. Kelly, et al.
Published: (2021-07-01)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
by: Vincent Cottin, et al.
Published: (2021-12-01)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
by: Martina Korfei, et al.
Published: (2018-01-01)

MicroRNA‐130a, a Potential Antifibrotic Target in Cardiac Fibrosis
by: Li Li, et al.
Published: (2017-11-01)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
by: Benjamin Seeliger, et al.
Published: (2022-08-01)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
by: Al-Fayoumi S, et al.
Published: (2018-05-01)

Role of antifibrotics in post-COVID fibrosis: Yes or no?
by: R Narasimhan
Published: (2021-01-01)

Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence
by: C. Robalo-Cordeiro, et al.
Published: (2017-09-01)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study
by: Cheng-Chun Yang, et al.
Published: (2022-04-01)

Functional xenon-129 magnetic resonance imaging response to antifibrotic treatment in idiopathic pulmonary fibrosis
by: Andrew D. Hahn, et al.
Published: (2023-06-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01)

Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
by: Anshika Jangra, et al.
Published: (2022-04-01)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
by: Ismail MH, et al.
Published: (2011-07-01)

Anti-Inflammatory, Antioxidant, and Antifibrotic Effects of Gingival-Derived MSCs on Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Xishuai Wang, et al.
Published: (2021-12-01)

Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
by: Yuya Aono, et al.
Published: (2020-09-01)

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis
by: Sonia Simón Serrano, et al.
Published: (2019-11-01)

Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models
by: Benjamin Bonnard, et al.
Published: (2021-01-01)

HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity
by: Hae Jin Kee, et al.
Published: (2013-07-01)

A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly
by: Kojiro Honda, et al.
Published: (2023-05-01)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
by: Shih-Lung Cheng, et al.
Published: (2022-09-01)

Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
by: Yuzo Suzuki, et al.
Published: (2021-09-01)

Antifibrotic drugs as therapeutic tools in resistant melanoma
by: Berta Sanchez‐Laorden, et al.
Published: (2022-03-01)

Antifibrotic effects of total or partial application of amniotic membrane in hepatic fibrosis
by: KARINA M. MAMEDE, et al.